Artamonov Mikhail Yu, Sokov Evgeniy L
Penn Medicine Princeton Health, Plainsboro, NJ 08536, USA.
Department of Algology and Rehabilitation, Peoples' Friendship University, Moscow 117198, Russia.
Curr Issues Mol Biol. 2024 Nov 8;46(11):12672-12693. doi: 10.3390/cimb46110752.
Mesenchymal stem cells are used most in regenerative medicine due to their capacities in differentiation and immune modulation. The intraosseous injection of MSC into the bone has been recommended because of expected outcomes for retention, bioavailability, and enhanced therapeutic efficacy, particularly in conditions involving the bone, such as osteoporosis and osteonecrosis. A review of the intraosseous delivery of mesenchymal stem cells in comparison with intravenous and intra-arterial delivery methods will be subjected to critical examination. This delivery mode fares better regarding paracrine signaling and immunomodulation attributes, which are the cornerstone of tissue regeneration and inflammation reduction. The local complications and technical challenges still apply with this method. This study was more focused on further research soon to be conducted to further elucidate long-term safety and efficacy of intraosseous mesenchymal stem cell therapy. Though much has been achieved with very impressive progress in this field, it is worth noting that more studies need to be put into place so that this technique can be established as a routine approach, especially with further research in biomaterials, gene therapy, and personalized medicine.
间充质干细胞因其分化和免疫调节能力而在再生医学中应用最为广泛。由于预期在留存、生物利用度和增强治疗效果方面有良好表现，尤其是在诸如骨质疏松症和骨坏死等涉及骨骼的病症中，推荐将间充质干细胞进行骨内注射到骨骼中。将对间充质干细胞的骨内递送与静脉内和动脉内递送方法进行比较审查。这种递送方式在旁分泌信号传导和免疫调节特性方面表现更佳，而这些特性是组织再生和减轻炎症的基石。这种方法仍然存在局部并发症和技术挑战。本研究更侧重于即将开展的进一步研究，以进一步阐明骨内间充质干细胞治疗的长期安全性和有效性。尽管该领域已经取得了很多令人瞩目的进展，但值得注意的是，需要开展更多研究，以便将该技术确立为常规方法，特别是在生物材料、基因治疗和个性化医学方面进行进一步研究。
